BMJ14m
Puberty blockers: UK bans drugs indefinitely after safety advice
The UK government has announced an indefinite ban on the use of puberty blockers for treating under 18s with gender dysphoria, after the Commission on Human Medicines advised that continuing to allow ...
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...
Le Lézard20m
Geron Announces Positive CHMP Opinion for RYTELOtm (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
The European Commission (EC), which has the authority to approve ... today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has... at ...
1,75,418 Ayushman Arogya Mandirs established & operationalised till Dec 10: Centre
A total of 1,75,418 Ayushman Arogya Mandirs (AAMs) have been established and operationalised, till December 10, by ...
PharmiWeb57m
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by its partner Takeda (TSE:4502/NYSE:TAK). Takeda received a national ...